Clinical Edge Journal Scan

Gene mutations may predict risk of vascular events in MDS


 

Key clinical point : Gene mutations involving ASXL1 were significantly associated with increased risk of vascular events in adults with myelodysplastic syndrome, but Trisomy 8 appeared to have a protective effect.

Major finding : Overall, the incidence of vascular disease in the study population was 27%; mutations in the ASXL1 in particular were significant predictors of vascular disease in multivariate analysis (odds ratio 4.2); however, both elevated ferritin and Trisomy 8 were significantly associated with a lower risk of vascular disease in low-risk MDS patients ( P = .043 and P = .036, respectively).

Study details : The data come from a retrospective analysis of 236 MDS patients aged 18 years and older who were seen and treated at a single center between 2010 and 2018.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Citation: Faber MG et al. eJHaem. 2020 Sept 28. doi: 10.1002/jha2.101.

Recommended Reading

ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
Federal Practitioner
COVID-19 may be more lethal in MDS patients
Federal Practitioner
New form of programmed cell death has cancer treatment implications
Federal Practitioner
Genome study identifies potential treatment target for myelodysplastic syndrome patients
Federal Practitioner
Dialysis predicts increased risk of myelodysplastic syndrome
Federal Practitioner
Bronchoscopy remains a safe choice for most patients with malignant hematologic disorders
Federal Practitioner
Most transfusion-dependent MDS patients report positive quality of life
Federal Practitioner
Luspatercept shows promise as efficacy marker in MDS patients
Federal Practitioner